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Available online 22 November 2018Background: A huge outbreak in the men-having-sex-with-men (MSM) has hit Europe during the years
2016–2018. Outbreak control has been hampered by vaccine shortages in many countries, and to minimize
their impact, reduction of antigen doses has been implemented. However, these measures may have conse-
quences on the evolution of hepatitis A virus (HAV), leading to the emergence of antigenic variants. Cases in vac-
cinated MSM patients have been detected in Barcelona, opening the possibility to study HAV evolution under
immune pressure.
Methods:We performed deep-sequencing analysis of ten overlapping fragments covering the complete capsid
coding region ofHAV. A total of 14578255 readswere obtained and used for the analysis of virus evolution in vac-
cinated versus non-vaccinatedpatients.We estimatedmaximumandminimummutation frequencies, and Shan-
non entropy in the quasispecies of each patient. Non-synonymous (NSyn) mutations affecting residues exposed
in the capsid surfacewere located, with respect to epitopes, using the recently described crystal structure of HAV,
as an indication of its potential role in escaping to the effect of vaccines.
Findings: HAV evolution at the quasispecies level, in non-vaccinated and vaccinated patients, revealed higher di-
versity in epitope-coding regions of the vaccinated group. Although amino acid replacements occurring in and
around the epitopes were observed in both groups, their abundance was signiﬁcantly higher in the quasispecies
of vaccinated patients, indicating ongoing processes of ﬁxation.
Interpretation: Our data suggest positive selection of antigenic variants in some vaccinated patients, raising con-
cerns for new vaccination polices directed to the MSM group.
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pen access article under the CC BY-Nhigh virus doses. Several outbreaks affecting this group have recently
occurred in Europe [1–5]. Particularly relevant is the still ongoing out-
break which started in 2016 and has affected over 4000 patients across
Europe. Three main circulating strains, belonging to genotype IA, have
been detected: VRD_521_2016 [6], RIVM-HAV16-090 [7], and V16-
25801 [8]. The control of this outbreak has been hampered by low
coverage vaccination in some countries, and by vaccine shortages,
which have obliged decision-making administrations to implement
some restrictions in the number of vaccine doses administered to pa-
tients and close contacts [9]. However, while these measures attempt
to avoid as much as possible the spread of the outbreak, and to protectC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Research in context
Evidence before this study
We searched PubMed using the search terms “hepatitis A” and
“MSM”. Since 1998, there has been an increase in outbreaks of
hepatitis A in the men-having-sex-with-men (MSM), with a ten-
dency over time to be larger and globally widespread. Hence, it
is evident that theMSMgroup is an endemic at-risk group for hep-
atitis A. A second search with the terms “hepatitis A” and “vac-
cine failure” was also done, rendering very few report cases,
indicating that the hepatitis A vaccines are highly efficient. How-
ever, these failures are always assumed to be due to a lack of se-
roconversion and never to the emergence of vaccine-escape
variants. Nevertheless, a previous study from our group described
the occurrence of such variants in an outbreak in the MSM group
in Barcelona in 2008.
Lately, there has been a problem of hepatitis A vaccine shortage,
which has required Public Health Agencies worldwide to imple-
ment changes in the vaccination schedules to reduce the antigenic
doses. The advent of the next generation sequencing techniques
(NGS) brings the possibility to deep-sequence serum samples
from non-vaccinated and vaccinated patients, with the aim to
seek for the emergence of antigenic variants.
Added value of this study
Our results represent the first ever-made analysis of the evolution
of HAV in vaccinated versus non-vaccinated patients. This study
has revealed that, due to the quasispecies dynamics of HAV, the
emergence of antigenic variants in and around the main epitopes
of the capsid occurs in both, vaccinated and non-vaccinated pa-
tients. However, only in vaccinated patients these variants in-
crease in number suggesting their positive selection. Particularly,
provided these antigenic variants had a high fitness, their circula-
tion in the MSM group may rapidly increase, and further expand
to the general population.
Implications of all the available evidence
Emergence of HAV antigenic variants may become a public health
threat and have consequences in the future usefulness of the pres-
ently available vaccines. To avoid as much as possible their selec-
tion, careful and systematic studies on the impact of new
vaccination policies directed to theMSMgroup are required, to en-
sure not only a high percent of seroconversion but also a high level
of seroconversion. Somemeasures may include the completion of
the vaccination schedule of two doses, the administration of
booster doses to vaccinees with low anti-HAV antibodies, and to
restrict as much as possible the vaccine post-exposure
prophylaxis.
Table 1
















M1 31 2902 8·2 2·5 × 105 5·7 + No
M2 25 1813 4·0 3·6 × 105 3·2 − No
M4 34 2722 NA 5·6 × 105 3·7 + No
M5 48 2847 6·5 5·3 × 104 5·7 − Yes
M6 34 4852 10·8 3·2 × 106 8·6 − Yes
M7 34 2784 2·1 2·4 × 105 7·1 + Yes
M9 28 4804 6·8 1·1 × 107 4·0 − No
M10 46 9000 8·9 1·3 × 108 4·9 − No
M17 NA 3662 13·0 9·1 × 104 7·1 + No
M30 28 528 5·9 1·2 × 105 2·0 − No
M46 24 NA 2·5 1·7 × 106 4·0 + Yes
M47 48 3148 6·5 3·3 × 106 4·0 − No
M48 NA 2358 6·8 1·1 × 106 4·3 + Yes
⁎ Cuttoff levels.
349A. Sabrià et al. / EBioMedicine 39 (2019) 348–357the patients' health, their potential implications on hepatitis A virus
(HAV) evolution should be a matter of debate, since the emergence of
vaccine escape variants has been previously described [10].
Despite the implementation of vaccine programs since 1999 [11],
the 2016–2018 outbreak has affected the MSM group in Barcelona in-
cluding some vaccinated patients. However, the incidence in Barcelona
has been much lower than in other parts of Spain in which no regular
vaccination campaigns exist. Next Generation Sequencing (NGS) of
the capsid coding region is the best approach for the analysis of the
HAV evolution in vaccinated and non-vaccinated patients, setting theground formeasures to avoid asmuch as possible the emergence of vac-
cine escape variants.2. Methods
2.1.1. Study design and participants
The 2016–2018 hepatitis A outbreak in theMSM group in Barcelona
affected a total of 159 patients at the end of 2017. Samples from 17% of
these patients (n=27)were used for analysis. Five out of these 27 sam-
ples belonged to vaccinated patients. Thirteen samples were chosen for
deep-sequencing including ﬁve from vaccinated patients, and eight ad-
ditional samples from non-vaccinated patients. These eight samples
were randomly chosen to cover the period of the outbreak.
All data related with the patients, including the clinical parameters
and vaccination status, were recorded by the Public Health Agency of
Barcelona and analysed anonymously. Data were collected on a routine
base, through the hepatitis A surveillance system of Barcelona, which
gathers information from physicians, electronic notiﬁcations, and labo-
ratory tests. The analyseswere carried out retrospectively. Therefore, no
informed consent was required because hepatitis A is a mandatory no-
tiﬁable disease. All data were treated in a strictly conﬁdential manner
according to the ethical principles of theHelsinki Declaration of 1964 re-
vised by the World Medical Organization in Edinburgh, 2000 and the
Organic Law 15/1999 of Data Protection in Spain.2.1.2. Molecular procedures
RNA extraction from 150 μl of serum was performed by using the
NucleoSpin RNA Virus kit (Macherey-Nagel, Germany), according to
the manufacturer's instructions, and eluted in 50 μl. cDNA synthesis
was performed using the SuperScript IV Reverse Transcriptase
(Invitrogen, ThermoFisher Scientiﬁc, MA, USA), using 5 μl of RNA and
the primers described in Tables 1–3 of the web extra material. The
cDNA length was of 355 and 1004 nt for genotyping and 3247 nt for
deep-sequencing.
Viral loads were determined as previously described [12], using ﬁve
μl of the extracted RNA and theRNAUltraSense™One-StepQuantitative
RT-PCR System (Invitrogen, ThermoFisher Scientiﬁc), and were
expressed as genome copies/ml of serum.
For genotyping, DNA ampliﬁcation was performed using the
FastStart High Fidelity PCR System, dNTPack (Roche Applied Science,
Switzerland), with 10 μl of cDNA and using the primers described in
Tables 1 and 2 of theweb extramaterial. Consensus sequenceswere ob-
tained using the ABI Prism® Big Dye™ Terminator Cycle Sequencing
Ready Reaction Kit v3·1 (Applied Biosystems, CA, USA) and the ABI
Prism 3700 automatic sequencer (Applied Biosystems). The reverse
Table 2
Genomic characterization of the quasispecies of the complete capsid coding region and part of 2A from vaccinated (n= 5) versus non-vaccinated patients (n= 8). Figures represent the
average of all the patients, belonging to a group, for each fragment. Boldﬁgures represent statistically signiﬁcant differences (p b 0·05) between thenon-vaccinated and vaccinated groups.
F1 correspond to a non-coding region and F2 includes a very small coding region, hence amino acid-related cells are empty.
Fragment Shannon entropy (Mean ± SD) Nucleotide Mutation Frequency (Mean ± SD) Amino acid Mutation Frequency (Mean ± SD)
Nucleotide Amino acid Minimum (×10−7) Maximum (×10−4) Minimum (×10−7) Maximum (×10−4)
VAC- F1 0·03 ± 0·02 2·54 ± 3·06 2·71 ± 1·98
F2 0·03 ± 0·02 1·17 ± 1·06 2·66 ± 2·26
F3 0·04 ± 0·02 0·02 ± 0·04 5·01 ± 4·16 2·73 ± 2·16 8·88 ± 7·03 3·95 ± 2·52
F4 0·04 ± 0·03 0·04 ± 0·06 4·10 ± 3·67 2·32 ± 2·15 5·44 ± 5·63 2·82 ± 3·79
F5 0·06 ± 0·02 0·03 ± 0·01 6·94 ± 6·72 3·60 ± 1·78 8·85 ± 7·49 6·55 ± 4·54
F6 0·05 ± 0·02 0·02 ± 0·01 1·99 ± 2·25 3·40 ± 2·67 2·82 ± 2·62 4·98 ± 6·04
F7 0·04 ± 0·01 0·01 ± 0·01 2·21 ± 2·17 2·64 ± 1·14 2·52 ± 3·14 4·23 ± 3·96
F8 0·03 ± 0·02 0·02 ± 0·02 1·72 ± 0·95 1·83 ± 1·42 3·33 ± 2·54 3·14 ± 3·25
F9 0·02 ± 0·01 0·01 ± 0·01 1·14 ± 0·91 1·13 ± 0·65 1·63 ± 1·96 1·23 ± 1·30
F10 0·05 ± 0·02 0·02 ± 0·02 1·84 ± 2·18 3·28 ± 2·95 3·31 ± 3·73 7·57 ± 9·50
VAC+ F1 0·04 ± 0·03 4·86 ± 5·73 3·27 ± 2·06
F2 0·03 ± 0·03 1·83 ± 1·40 2·28 ± 2·63
F3 0·04 ± 0·03 0·02 ± 0·01 3·99 ± 5·57 2·98 ± 2·65 4·72 ± 2·76 4·32 ± 4·24
F4 0·07 ± 0·05 0·03 ± 0·03 7·55 ± 7·65 7·53 ± 6·82 10·6 ± 9·14 11·5 ± 14·6
F5 0·03 ± 0·01 0·01 ± 0·01 1·71 ± 1·42 2·05 ± 0·88 2·41 ± 3·08 1·77 ± 2·29
F6 0·04 ± 0·04 0·02 ± 0·02 1·97 ± 1·28 3·11 ± 3·92 3·78 ± 3·76 3·13 ± 4·22
F7 0·05 ± 0·02 0·03 ± 0·01 2·29 ± 2·48 3·40 ± 2·08 3·95 ± 5·28 8·15 ± 6·21
F8 0·08 ± 0·03 0·05 ± 0·01 3·88 ± 4·47 7·23 ± 4·46 8·97 ± 11·3 15·9 ± 12·9
F9 0·06 ± 0·04 0·02 ± 0·01 4·48 ± 3·30 4·33 ± 3·27 8·07 ± 8·07 5·99 ± 4·72
F10 0·05 ± 0·02 0·03 ± 0·02 4·05 ± 3·88 3·49 ± 1·74 10·1 ± 11·5 6·54 ± 6·06
350 A. Sabrià et al. / EBioMedicine 39 (2019) 348–357strand was sequenced and all mutations conﬁrmed in the forward
strand.
For deep-sequencing, DNA ampliﬁcation was performed in two
steps. In the ﬁrst PCR, 10 μl of cDNA were ampliﬁed using the FastStart
High Fidelity PCR System, dNTPack (Roche) and the primers described
in Table 3 of theweb extra material, to reach a singlemolecule covering
the whole capsid coding region and a fragment of 2A (Fig. 1). Ten
nested-PCRs were performed to amplify each of ten fragments, using
the same kit but with 5 μl of DNA from the ﬁrst-round PCR as template.
The average fragment size was 437-bp (minimum of 424-bp and
maximum of 448-bp) with overlapping regions ranging from 76-bp to
113-bp (Fig. 1). Nested-PCR products were puriﬁed from agarose gel
bands (QIAquick Gel Extraction Kit, QIAgen, CA, USA), quantiﬁed
(Qubit™ dsDNA BR Assay Kit, Invitrogene, ThermoFisher), and tested
for quality (Bioanalyzer DNA 1000, Agilent, CA, USA). PCR products
from a single patient were pooled at a normalized concentration and
puriﬁed (Agentcourt® AMPure® XP, Beckman Coulter, CA, USA). An-
other normalizationwas performed to 1·5 ng/μl, followed by the library
preparation protocol using the Kapa HyperPrep Kit (Roche Applied
Science, CA, USA), and the SeqCap Adapter Kit A/B (24 Index.
Nimblegen, Roche) for the pool indexing. A second cleanup was per-
formed (Kapa Pure Beads, KapaBiosystems, Roche) and a quality control
assay was done using the Bioanalyzer. Each pool was normalized to
4 nM, and appropriated volumes of each pool were added to the ﬁnal li-
brary, which was quantiﬁed by LightCycler480 (Kapa Library Quantiﬁ-
cation Kit, KapaBiosystems, Roche). Last dilution of the Library was
prepared and mixed with an internal DNA control (PhiX control V3,
Illumina, CA, USA) before being sequenced using the MiSeq platform
with MiSeq Reagent Kit V3 (Illumina).Table 3
Analysis of the NSyn mutations detected in the complete capsid coding region. Data rep-
resent the average number of NSynmutations per patient. In brackets appears the propor-
tion of these mutations present at frequencies above 5%.
VP2 VP3 VP1
Non-Vaccinated 6·13 (0·02) 6·50 (0·10) 4·88 (0·03)
Vaccinated 6·20 (0·13) 3·60 (0·11) 9·60 (0·20)2.1.3. Phylogenetic analysis
Phylogenetic analyses of a fragment of 255-bp (spanning positions
2958–3230) from the VP1/2A, and a 1004-bp fragment (spanning posi-
tions 2208–3212) including the complete VP1 sequence and a short
fragment of 2A were performed with the neighbour-joining method
(distance calculation by the Kimura-2-parameter correction; pairwise
deletion) implemented in the MEGA7 program [13]. Results were vali-
dated by 1000 bootstrap replicates. Genotype assignment was based
on clustering with reference strains from the sequence database of the
European Network [14], and all sequences were deposited to GenBank
with accession numbers MH476486 to MH476511 and MK116906 to
MK116923.
The same sequences were translated into amino acids and phyloge-
netic trees based on a sequence of 91 amino acids (spanning positions
251–300 from VP1 and 1–41 from 2A), and on a sequence of 334
amino acids (spanning positions 1–300 from VP1 and 1–35 from 2A)
were similarly performed. Amino acid dendograms were constructed
using the Neighbour-Joining method with distance calculation using
the Poisson correction method.2.1.4. Ultra-deep sequencing data management
A bioinformatic haplotype-centric procedure was used to exclude
full reads that do not meet minimum quality requirements. Brieﬂy,
once acquiring raw data from MiSeq (fastq), the ﬁrst step included the
overlap of paired-end reads using FLASH [15,16]. The FLASH parameters
were stablished as a minimum overlap between the paired-end reads,
R1 and R2, of 20 bp with a maximum of 10% differences. Reads not ful-
ﬁlling this requirement were discarded. Next, reads were demultipled
by speciﬁc primers to obtain a fasta ﬁle by amplicon and strand. Reads
were then collapsed into haplotypes with corresponding frequencies.
Haplotypes were aligned with the reference sequence, and haplotypes
containing more than two indeterminations, three gaps or 99 differ-
ences were also discarded. Accepted indeterminations and gaps were
repaired as per the contents of the dominant haplotype. The intersec-
tion between forward and reverse haplotypes with abundances not
below 0·1% was performed. Finally, all haplotypes with abundances
below 0·5% were excluded. All sequences were deposited to GenBank
with accession number SRP151545.
The quasispecies diversity was analysed by calculating the
minimum and maximum mutation frequencies (synonymous and
Fig. 1.Diagramof the fragments used for the deep-sequencing analysis covering, the 5′non-coding-region (5′NCR), the complete capsid region (VP4, VP2, VP3, andVP1), and a fragment of
the 2A region.
351A. Sabrià et al. / EBioMedicine 39 (2019) 348–357non-synonymous), and the normalized Shannon entropy (measure of
diversity based on the frequency of haplotypes bearing synonymous
and non-synonymous mutations), as previously described [17]. All
these parameters were calculated for all ten fragments (F1–F10) in the
quasispecies of each patient, and expressed as the average of all the
patients belonging to the non-vaccinated or the vaccinated groups.
The synonymous mutations per synonymous site (Ks), and the
non-synonymous mutations per non-synonymous site (Ka) of the hap-
lotypes from each quasispecies were calculated using the DnaSP v6·0
software [18,19]. The average of the Ks and Ka of each haplotype was
normalized by its frequency and the Ka/Ks ratio calculated. Finally, the
average of the Ka/Ks ratios of all haplotypes from the non-vaccinated
and vaccinated groupswasﬁgured and used as ameasure of positive se-
lection when its value was N1.
2.1.5. Study of the amino acid replacements located on the capsid surface
Analysis of the location of the replacements on the surface of the
HAV protomer was performed using the coordinates from the crystal
structure [20] (RCSB accession code: 4QPI), and the Discovery Studio
software (Dassault Systèmes BIOVIA, Discovery Studio Modeling Envi-
ronment, San Diego: Dassault Systèmes, 2016).
Mutations detected in the protomer surface were classiﬁed as lo-
cated in, close, or far from the epitopes. Mutations directly affecting
the epitopeswere those coincidentwith the residues deﬁningmonoclo-
nal antibodies (mAbs) escape mutants [21,22], and those included in a
mAb footprint area [23]. Additionally, mutations located at a distance
of 1–2 residues from the residues identiﬁed in mAbs resistant mutants
were considered to be closely located to these epitopes.
2.2. Statistical analysis
Statistical differences of the different parameters under analysis be-
tween groups of patients were determined using the Student t-test (un-
paired) or the Mann-Whitney Rank Sum Test using the SigmaPlot
version 11; p values b 0·05 were considered statistically signiﬁcant.
2.3. Role of the funding source
No role of the funding sources. No conﬂict of interest to declare. The
corresponding authors had full access to all the data in the study and
had ﬁnal responsibility for the decision to submit for publication.
3. Results
The European hepatitis A outbreak affecting the men-having-sex-
with-men (MSM) in the season 2016–2017 affected 159 patients in
the city of Barcelona, including six vaccinated patients. The genotype
of 27 isolates was determined, proving that 74%, 22%, and 4% of the
strains were related with strains VRD_521_2016, RIVM-HAV16-090,
and V16-25801, respectively, andwere also closely related to the strains
isolated in a previous outbreak that occurred in 2008–09 in Barcelona in
the MSM group (Fig. 2).
Six out of the 159 patients had been vaccinated (3·77% of all cases),
and ﬁve of these samples (3·14% of all cases), along with eight addi-
tional samples from non-vaccinated patients (5·03% of all samples)
were used for the comparative analysis. All sera samples were obtained
during theﬁrstweek after the onset of symptoms. Overall, no signiﬁcantdifferenceswere found in the IgM levels or in the clinical parameters be-
tween the non-vaccinated and vaccinated patients (Table 1). Surpris-
ingly, although vaccinated patients tended to show lower HAV viral
loads, the difference was not statistically signiﬁcant (Fig. 3a). Neither
HIV-infected patients did show signiﬁcantly different HAV viral loads
than the HIV-non-infected patients, although they tended to be lower
(Fig. 3b).
Deep-sequencing analysis was performed on ten fragments (F1–
F10) covering the 5′ non-coding-region (5′NCR), the complete capsid
region, and a fragment of the 2A region (Fig. 1). A total of 14578255
reads were obtained and used for the analysis of virus evolution in vac-
cinated versus non-vaccinated patients. The informative content (IC) of
each position, obtained using overlapping windows of ten amino acid
sliding every three amino acids in amulti-alignment of all the sequences
from vaccinated versus non-vaccinated patients, revealed that overall
the amino acid variability of the HAV quasispecies is extremely low.
The average IC was not different between the non-vaccinated patients
and vaccinated patients. However, despite this high degree of conserva-
tion, few regions with clear variability differences between the non-
vaccinated and vaccinated groups were observed. Additionally, the
analysis of the genetic parameters including the entropy and the nucle-
otide and amino acidmutation frequencies also revealed differences be-
tween both groups of patients (Table 2). Integrating the results of the IC
and the genetic parameters it was concluded that the region encoded in
the fragment F5 (VP3) and the region encoded in fragments F7-F9 (VP1)
were more variable in the non-vaccinated patients and vaccinated pa-
tients, respectively. These data could suggest the occurrence of positive
selection in VP1 and of purifying selection in VP3 in the vaccinated
patients.
To look deep inside these possibilities, we plotted the frequency of
NSyn mutations detected in the quasispecies of each patient all along
the capsid (Fig. 4b). The average number of NSyn mutations in the
VP1 coding region in the vaccinated group was clearly above the non-
vaccinated group, and yet more remarkably a higher proportion of
NSyn mutations at frequencies above 5% (Fig. 4b and Table 3). In con-
trast, the average number of NSyn mutations in the VP3 coding region
in the vaccinated group was clearly below the non-vaccinated group
(Fig. 4b and Table 3). Again this suggested purifying selection in VP3,
which could be related to some negative epistatic effects increasing
the exposure of epitopes, and positive selection in VP1 that was further
analysed.
The analysis of NSyn mutations located on the surface of the HAV
protomer [20] revealed similar results (Fig. 5). Among the non-
vaccinated patients, 11·69% of the NSyn replacements involved resi-
dues from antigenic sites, 24·68% involved residues closely located to
these sites, and 63·63%were randomly distributed. Similarly, in the vac-
cinated patients, 4·88% and 36·59% of the replacements were in or
closely located to the antigenic sites, respectively, and 58·53%were ran-
domly distributed on the surface of the protomer. Additionally, the av-
erage number of NSyn mutations per patient located in or close to the
epitopes, was similar in the non-vaccinated and vaccinated groups
(Table 4). However, the most striking difference was the abundance of
the haplotypes bearing mutations located in or near the antigenic sites
in the quasispecies. While in the non-vaccinated patients these variants
were found at frequencies below 5%, in the vaccinated patients were
much more abundant, again indicating the action of positive selection,
Fig. 2. Phylogenetic analysis of HAV strains isolated frompatients of themen-having-sex-with-men (MSM) 2016–2018 outbreak from Barcelona. (a) Phylogenetic tree based on a 255-bp
fragment (spanning positions 2958–3230) from the VP1/2A protein. (b) Phylogenetic tree based on a sequence of 91-amino acids (spanning positions 251–300 from VP1 and 1–41 from
2A). (c) Phylogenetic tree based on a 1004-bp fragment (spanning positions 2208–3212) including the complete VP1 sequence and a short fragment of 2A. (d) Phylogenetic tree based on a
sequence of 334-amino acids (spanning positions 1–300 from VP1 and 1–35 from 2A). Nucleotide dendrograms were constructed using the neighbour-joining method with distance
calculation by the Kimura-2-parameter, and performing a bootstrap of 1000 replicates. Amino acid dendograms were constructed using the Neighbour-Joining method with distance
calculation using the Poisson correction method. Samples from vaccinated individuals (n = 5) are underlined, samples from HIV-infected patients (n = 6) are indicated with the “†”
symbol. Samples further analysed by MiSeq Illumina (n = 13) are indicated with “*”. The three main circulating strains in Europe related to this outbreak, VRD_521_20166, RIVM-
HAV16-0907, and V16-258018A are included, and labelled in bold, as well as ﬁve representative samples from a previous MSM outbreak in Barcelona from 2008 to 09 (MSM08-09). Ad-
ditionally, eleven reference strains representative of all subgenotypes (subgenotype IA: AB020565, EU13137, X83302; subgenotype IB: M14707, M59808, DQ646426, subgenotype IC:
HQ401240; subgenotype IIA: AY644676; subgenotype IIB: AY644670; subgenotype IIIA: AB279733; subgenotype IIIB: AB425339), including the HM175 strain used in the TWINRIX vac-
cine (subgenotype IB), were also added. All tested samples were obtained in the period 2016–2017.
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Fig. 3. HAV viral loads. (a) Boxplot of the average virus load in sera from the non-
vaccinated and vaccinated groups. (b) Boxplot of the average virus load in sera from
HIV-non-infected and HIV-infected groups. Bottom and upper limits of the boxes
represent the 25th and 75th percentiles, respectively. When present (n N 9), bottom and
upper whiskers represent 10th and 90th percentiles, respectively. The median is
represented by a solid black line and the average as a dotted red line.
Fig. 4. Informative content (IC) of each amino acid position along the capsid, and analysis o
performed using overlapping windows of 10 amino acids sliding every 3 amino acids. IC va
point (amino acid position) corresponds to the mean IC from all the sequences of a given
vaccinated group. Values have been normalized by the frequency of each substitution and th
the non-vaccinated patients (n= 8; black dots) and vaccinated patients (n= 5; red dots); bl
5% frequency; points over this line represent high-frequency mutations.
353A. Sabrià et al. / EBioMedicine 39 (2019) 348–357particularly in the VP1 epitopes (Fig. 5 and Table 4). Overall, 42·86%,
25·00%, and 32·14% of the NSyn replacements located in and around
the antigenic sites in the quasispecies of the non-vaccinated group,
and 43·75%, 37·50%, 18·75% in the vaccinated group, were in the VP1
immunodominant site [21], the glycophorin A binding site located in
the VP1 protein [22,24], and the putative receptor binding site in the
pentamer interface expanding from VP2 to VP3 proteins [23], respec-
tively (Figs. 5 and 6a). More remarkably, the average proportion of hap-
lotypes, from the different patient quasispecies, bearing mutations in
and around these sites were of 1·53%, 1·39% and 1·54%, and 4·38%,
2·76% and 1·56% in the non-vaccinated and vaccinated groups, respec-
tively (Fig. 6b). Of note, patient M5 bore the replacements Arg to Ser at
position 138 of VP1 (close to the glycophorin A binding site epitope),
and Asn to Ile at position 67 of VP3 (close to the VP3 region of the puta-
tive receptor binding site), at frequencies of 9·5% and 5·9%, respec-
tively; additionally, patient M6 bore the replacement Leu to Ser at
position 243 of VP1 (close to the VP1 immunodominant site) at a fre-
quency of 12·7% (Fig. 5). In contrast, vaccinated patients M7, M46 and
M48 showed the same abundance of antigenic variants than non-
vaccinated patients.
Altogether, the analysis of the genomic features and the location of
mutations on the protomer surface, suggested positive selection of re-
placements in the immunodominant site (encoded in fragments F8
and F9) and in the glycophorine A binding site (encoded in fragment
F9) in the vaccinated group. In fact, the ratio of NSyn to synonymous
variants (Ka/Ks), which is an indication of positive selection when its
value is N1, of the F8 and F9 fragments was signiﬁcantly (p b 0·001)
higher in the vaccinated group (Ka/Ks = 1·15 ± 1·13) than in the
non-vaccinated group (Ka/Ks = 0·51 ± 0·62). In contrast, no differ-
ences were found in the Ka/Ks of the putative receptor binding site
(encoded in fragments F3- F6) between the non-vaccinated (Ka/Ks =f the frequency of the NSyn mutations. (a) The analysis of the informative content was
lues (in bits) range from 0 (maximum variability) to 4·32 (minimum variability). Each
group. The black line corresponds to the non-vaccinated group and the red line to the
e number of sequences per group. (b) Frequency (%) of the NSyn mutations detected in
ack dots are more common due to the higher n. The horizontal green line represents the
Fig. 5. Location of the variants affecting residues in and around the antigenic sites of theHAVcapsid. (a) Protomers fromnon-vaccinated patients (M1,M2,M4,M9,M10,M17,M30, andM47). (b) Protomers fromvaccinated patients (M5,M6,M7,M46
andM48). Green protein corresponds to VP2, red to VP3 and blue to VP1. Protomers used to locate the replacements were extracted from the recently resolved crystal structure of HAV [18]. Epitopes (yellow residues) were identiﬁed either by mAb
escapemutants [19,20] (VP1 and VP3) ormAb footprints [21] (VP2 and VP3). Grey residues representmutations directly affecting the epitopes. Clear blue residues representmutations located at a distance of 1–2 residues from the epitopes identiﬁed










Analysis of the NSyn mutations located in or close to the capsid epitopes. Data represent
the number of mutations in the different patients, the average number of mutations,
and the proportion of these mutations present at frequencies above 5%, in the non-vacci-
nated and vaccinated groups.
Mutations per patient
Groups of patients
Non-Vaccinated VP2 VP3 VP1 Total
M1 0 2 7 9
M2 0 0 0 0
M4 0 3 2 5
M9 1 1 2 4
M10 0 2 0 2
M17 0 0 1 1
M30 1 0 1 2
M47 0 2 3 5
Average of mutations per patient
0·25 1·25 2·00 3·50
Proportion of mutations above 5%
0·00 0·00 0·00 0·00
Mutations per patient
Vaccinated
M5 0 2 4 6
M6 0 1 1 2
M7 0 0 2 2
M46 0 0 3 3
M48 0 0 3 3
Average of mutations per patient
0·00 0·60 2·60 3·20
Proportion of mutations above 5%
0·00 0·33 0·15 0·19
355A. Sabrià et al. / EBioMedicine 39 (2019) 348–3570·54± 0·60) and vaccinated groups (Ka/Ks= 0·49± 0·58), indicating
lack of positive selection.
4. Discussion
In the current scenario of hepatitis A vaccine shortage, several coun-
tries have implemented as a ﬁrst measure the reduction of the number
of vaccine doses and the antigen content of the doses [9]. Public Health
England recommendations for the vaccination of the MSM group in
shortage settings, are among themost rational, and based on the follow-
ing criteria. For immunocompetent adults under 60 years of age, a single
dose of vaccinewith half the adult antigen contentmay be enough sinceFig. 6. Analysis of NSyn mutations located in and around the main antigenic sites in the
non-vaccinated and vaccinated groups. (a) Percent of all NSyn mutations located in or
around the antigenic sites distributed in the VP1 immunodominant site (dark blue), the
VP1 glycophorin A binding site (red) and the VP2, VP3 putative receptor binding (clear
blue). (b) Average of the abundance of haplotypes bearing the NSyn mutations from (a).its immunogenicity, at onemonth, is equivalent to the complete antigen
content. For patients immunocompromised, with chronic liver disease
or aged over 60 years, due to a lower and slower response to vaccine,
a higher antigen content dose is required [25]. Recommendations
from the Spanish Health System [26] are less comprehensive and
based on the administration of a single dose and twodoses in the immu-
nocompetent and the immunocompromised patients, respectively.
However, despite the need to preserve the vaccine stocks, the implica-
tions that the reduction of the overall antigen administered may have
on virus evolution and the potential emergence of variants escaping
vaccine protection are mostly unknown [27]. Although HAV is an anti-
genically stable virus due to genetic and structural constraints [28], im-
mune pressure selection may force the emergence of such variants and
even of a new serotype.
In this study, we have analysed the evolution of HAV in ﬁve cases
from vaccinated patients in comparison to the evolution in eight non-
vaccinated patients. As expected, mutations located in or close to the
capsid antigenic sites were found in both, vaccinated and non-
vaccinated patients, and may be explained by the higher tolerance to
mutation of the exposed capsid regions, or to the hitchhiking of replace-
ments at antigenic sites belonging to genomes selected for other traits
or by genetic drift [22,29]. However, the signiﬁcantly higher Ka/Ks of
the immunodominant and glycophorin A binding sites containing frag-
ments, combinedwith the higher proportion of variants in these sites in
the quasispecies, suggest positive selection of these variants in the vac-
cinated patients.
The cause of these vaccine failures is unknown. HAV vaccination is
estimated to provide immunity up to twenty years in the general popu-
lation [30], and at least up to ten years in the HIV-infected patients with
high seropositivity rates [31]. Two failures were observed in optimally-
vaccinated patients. The ﬁrst patient received two doses of the dual pae-
diatric TWINRIX vaccine during his childhood (M5), was 34-year old
and HIV-non-infected, and showed a moderate diversity of antigenic
variants but otherwise representing 20% of the virus population, and
likely towards ﬁxation of at least two mutations. The time lapse since
the vaccination was over twenty years, and this could have caused a re-
duction of the antibody titres, allowing the virus to replicate in the pres-
ence of antibodies, and hence facilitating the selection of escaping
variants. Unfortunately, anti-HAV antibody titres are not usually deter-
mined in the vaccinated patients. The secondpatient received twodoses
of the dual adult TWINRIX vaccine two years before the onset of hepati-
tis A (M7), was immunocompetent HIV-infected, and showed amoder-
ate diversity of antigenic variants but none of them at a high proportion.
The other three failures were in suboptimally-vaccinated patients. The
ﬁrst and second patients received a single dose of the adult dual
TWINRIX vaccine 15 months (M46) and 18 months (M48) before the
onset of the disease, were both immunocompetent HIV-infected, and
again showed moderate diversity of antigenic variants with none at
high proportions. Vaccine failures after a single dose have been previ-
ously described but data on virus evolution has never been discussed
[32]. The third patient, that received two doses of the adult dual
TWINRIX vaccine during the incubation period (M6), was 34-year old
and HIV-non-infected, and showed a moderate diversity of antigenic
variants but with one, affecting the immunodominant site, at a propor-
tion of 12·7%, again suggesting an ongoing process of ﬁxation. Post-
exposure vaccination is increasingly being used to prevent cases
among contacts, and although is a good preventive measure, failure
rates of 4·4%-6·9% have been described [33,34]. HAV replication takes
place mostly during the incubation time of the disease and again the
low concentration of antibodies would have allowed the virus to repli-
cate in their presence enabling the selection of escaping variants. Re-
garding the three cases in vaccinated HIV-infected patients, with a
repertoire/proportion of HAV antigenic variants similar to that of the
non-vaccinated patients, the failure could likely be due to a lack of re-
sponse to the vaccine as previously described [35]. Alternatively, it
could be due to a less prone antigenic variant emergence, since HIV-
356 A. Sabrià et al. / EBioMedicine 39 (2019) 348–357infected patients showed a tendency to carry a lower HAV genome load.
This tendency contrastswith the data available in the literature showing
average genome loads of 103–107 and of 107–108 genome copies/ml of
sera in HIV-non-infected patients [36,37] and HIV-infected patients
[12,38], respectively.Whether this change in theHAV replication capac-
ity observed in HIV-infected patients is related to the recent introduc-
tion of new antivirals in the anti-HIV therapy that could act on HAV,
remains unknown.
Antigenic variants arising around the immunodominant and the
glycophorin A binding sites show higher ﬁtness in the presence of anti-
bodies than the wild-type virus [22]. Consequently, they may represent
a public health threat in populations with high anti-HAV
seroprevalences, including endemic regions and countrieswith vaccina-
tion programs.
The MSM group is becoming endemic for hepatitis A requiring spe-
ciﬁc vaccination policies. As expected the number of cases among the
vaccinated patients was very low, but the molecular analysis of their
quasispecies is essential for the analysis of HAV evolution under im-
mune pressure. Despite the overall low number of samples included
in this study, still some recommendations aiming to avoid the emer-
gence of vaccine escape variants can be formulated: vaccination sched-
ule must be completed, booster doses should be administered to those
vaccinated long time ago or with low anti-HAV antibodies, and vaccine
post-exposure prophylaxis should be reconsidered. These recommen-
dations are particularly relevant for the MSM group, especially in
those countries and regions where the virus is endemic.
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